Publications by authors named "Muriel Richard"

Claim this Profile
D
Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia.
Martin Hutchings, Koorosh Korfi, Pau Montesinos, Armando Santoro, Hsin-An Hou, Muriel Richard

Blood Neoplasia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.
Loic Verlingue, Antoine Italiano, Hans Prenen, Eva Maria Guerra Alia, Diego Tosi, Muriel Richard

EBioMedicine· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer.
Hans Prenen, Sanjeev Deva, Bhumsuk Keam, Colin R Lindsay, Iwona Lugowska, Muriel Richard

Clin Cancer Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patients.
Marion Ort, Jasper Dingemanse, Chih-Hsuan Hsin, Muriel Richard, Eva Huehn

Basic Clin Pharmacol Toxicol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects.
Benjamin Berger, Sander Brooks, Rob Zuiker, Muriel Richard, Clemens Muehlan

CNS Drugs· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
Muriel Richard, Priska Kaufmann, Marion Ort, Rüdiger Kornberger, Jasper Dingemanse

CNS Drugs· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-man study of ACT-709478, a novel selective triple T-type calcium channel blocker.
Muriel Richard, Priska Kaufmann, Rüdiger Kornberger, Jasper Dingemanse

Epilepsia· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis